Cargando…

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer

Detalles Bibliográficos
Autor principal:	Nucera, Carmelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366830/ https://www.ncbi.nlm.nih.gov/pubmed/30774767 http://dx.doi.org/10.18632/oncotarget.26591

Ejemplares similares

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors
por: Zhu, Xuguang, et al.
Publicado: (2018)

Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer
por: Li, Wenbo, et al.
Publicado: (2023)

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
por: Enomoto, Keisuke, et al.
Publicado: (2021)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
por: Funck-Brentano, Elisa, et al.
Publicado: (2020)

Evolution of resistance to thyroid cancer therapy
por: Nucera, Carmelo
Publicado: (2016)

Bromodomain-containing protein 4 is critical for the antiproliferative and pro-apoptotic effects of gambogic acid in anaplastic thyroid cancer
por: Wang, Yonghui, et al.
Publicado: (2018)

Targeting Thyroid Cancer Microenvironment: Basic Research and Clinical Applications
por: Nucera, Carmelo
Publicado: (2013)

Molecular-targeted therapy for advanced anaplastic thyroid cancer combined with nutritional support
por: Maegawa, Yuka, et al.
Publicado: (2019)

Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer
por: Fazeli, Sasan, et al.
Publicado: (2019)

Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles
por: Lam, Fred C., et al.
Publicado: (2018)

Bromodomain inhibitors and cancer therapy: From structures to applications
por: Pérez-Salvia, Montserrat, et al.
Publicado: (2016)

Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management
por: Yuan, Jiaqian, et al.
Publicado: (2022)

Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity
por: Watts, Ellen, et al.
Publicado: (2019)

Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer
por: De Andrade, James P., et al.
Publicado: (2017)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer
por: Denaro, Nerina, et al.
Publicado: (2013)

Anaplastic thyroid cancer: outcomes of trimodal therapy
por: Houlihan, Orla A., et al.
Publicado: (2021)

Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment
por: Duquette, Mark, et al.
Publicado: (2013)

Corrigendum: Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells With BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment
por: Duquette, Mark, et al.
Publicado: (2020)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy
por: McGonagle, Elizabeth R., et al.
Publicado: (2019)

Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: A case report
por: Ma, Dong-Xu, et al.
Publicado: (2022)

Targeting Glycogen Metabolism as a Novel Therapeutic Approach in Anaplastic Thyroid Cancer
por: Davidson, Cole, et al.
Publicado: (2021)

Anaplastic thyroid cancer: genome-based search for new targeted therapy options
por: Hescheler, Daniel Alexander, et al.
Publicado: (2022)

Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma
por: Meng, Wei, et al.
Publicado: (2018)

Papillary Thyroid Cancer Differentiating Into Anaplastic Carcinoma With Near-Complete Response to Targeted Dabrafenib/Trametinib Combination Therapy
por: Kulkarni, Pruthali, et al.
Publicado: (2021)

MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
por: Harder, Anja
Publicado: (2021)

Targeting transcriptional regulators for treatment of anaplastic thyroid cancer
por: Lee, Woo Kyung, et al.
Publicado: (2021)

Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer
por: Choi, Yoon Ju, et al.
Publicado: (2021)

ETS-targeted therapy: can it substitute for MEK inhibitors?
por: Tetsu, Osamu, et al.
Publicado: (2017)

Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors
por: McKeown, Michael R, et al.
Publicado: (2014)

A New Aurora in Anaplastic Thyroid Cancer Therapy
por: Baldini, Enke, et al.
Publicado: (2014)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B Bromodomain
por: Ferguson, Fleur M., et al.
Publicado: (2013)

Bromodomains as therapeutic targets
por: Muller, Susanne, et al.
Publicado: (2011)

Clinical Outcome, Role of BRAF(V600E), and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?
por: Nucera, Carmelo, et al.
Publicado: (2012)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

BI-847325, a selective dual MEK and Aurora kinases inhibitor, reduces aggressive behavior of anaplastic thyroid carcinoma on an in vitro three-dimensional culture
por: Samimi, Hilda, et al.
Publicado: (2022)

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
por: Gao, Xiaoni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_23t7bll1hlf6kp0foatbsievta